Researchers at McGill University have developed engineered nanoparticle carriers capable of delivering cancer drugs specifically to diseased lymph nodes while sparing healthy tissue, according to a study published in Proceedings of the National Academy of Sciences. This targeted approach has demonstrated reduced toxic side effects in mice compared to conventional whole-body treatments, addressing the challenging stage when cancer has spread into the lymphatic system.
The lymphatic system plays an essential role in coordinating immune responses throughout the body, yet current treatment approaches often force surgeons to remove affected nodes when cancer metastasizes there. The nanoparticle method developed by the McGill team represents a potential alternative that could preserve lymph node function while treating the disease. The research group is currently conducting additional animal safety tests before pursuing human clinical trials.
The study’s findings suggest these engineered nanoparticles could potentially be adapted to deliver various cancer treatments, including novel therapies being developed by biotechnology companies. The research publication is available through the Proceedings of the National Academy of Sciences at https://www.pnas.org. While the current research focuses on animal models, the implications for human cancer treatment are significant, particularly for patients with lymphatic system involvement where treatment options are limited and often invasive.
Targeted drug delivery systems like these nanoparticles represent an important advancement in precision medicine approaches to cancer treatment. By concentrating therapeutic agents specifically at disease sites, such systems could minimize damage to healthy tissues and reduce the debilitating side effects commonly associated with chemotherapy and other cancer treatments. The McGill team’s work contributes to growing research efforts aimed at developing more selective and effective cancer therapies.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is McGill Researchers Develop Nanoparticle System for Targeted Lymph Node Cancer Treatment.